Notably, neoadjuvant endocrine therapy was considered as a first appropriate treatment for patients diagnosed with stage I-III estrogen receptor–positive breast cancer in 2016 or after, to be consistent with the 2016 National Comprehensive Cancer Network guideline update (8). Here, ESR1 is linked to breast cancer.